Initial management of prostate cancer: First year experience with the Norwegian National Prostate Cancer Registry

BJU International

Volumn 105, Issue 6, 2010, Pages 805-811

  Hernes, Eivor ^a,b   Kyrdalen, Anne ^c   Kvåle, Rune ^a   Hem, Einar ^d   Klepp, Olbjørn ^e   Axcrona, Karol ^c   Fosså, Sophie D ^a,f  

^a CANCER REGISTRY OF NORWAY   (Norway)

^b Hospital of Buskerud   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

Local treatment; National registries; Prostate cancer; Risk groups

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER REGISTRY; CONTROLLED STUDY; EXPERIENCE; GROUPS BY AGE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; EPIDEMIOLOGIC METHODS; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; NORWAY; PRACTICE GUIDELINES AS TOPIC; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGISTRIES; TREATMENT OUTCOME;

EID: 77649246720     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08834.x     Document Type: Article

References (24)

1. Kvåle R, Auvinen A, Adami HO et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007 99 : 1881 1887
2. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I. International comparisons. BJU Int 2002 90 : 162 173 (Pubitemid 34779587)
3. Adolfsson J, Garmo H, Varenhorst E et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007 41 : 456 477
4. Aus G, Abbou CC, Heidenreich A et al. Guidelines on Prostate Cancer. European Association of Urology. Prostate cancer (update 2003) ISBN 90-70244-06-3. Available at: http://www.uroweb.org. Accessed August 2009
5. Norwegian Medicines Agency. Treatment of prostate cancer. Therapy recommendation 2004. Available at: http://www.legemiddelverket.no/upload/16116/ NyL4,2004.pdf. Accessed August 2009
6. Wittekind LH, Sobin Ch eds. UICC TNM Classification of Malignant Tumours, 6th edn. New York : Wiley Liss, 2002 : 184 187
7. FossåSD, Lilleby W, Waehre H et al. Definitive radiotherapy of prostate cancer: the possible role of staging lymphadenectomy. Int J Radiat Oncol Biol Phys 2003 57 : 33 41
8. Widmark A, Klepp O, Solberg A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet 2009 373 : 301 308
9. Bolla M, van Poppel H, Collette L et al. Post-operative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 2005 366 : 572 578
10. D'Amico AV, Whittington R, Malkowicz SB et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001 166 : 2185 2188
11. Bill-Axelson A, Holmberg L, Filén F et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial. J Natl Cancer Inst 2008 100 : 1144 1154
12. Schröder FH. Screening for prostate cancer (PC) -an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Urol Oncol 2008 26 : 533 541
13. Parker C, Melia J. Prostate-specific antigen testing in healthy men: a U.K: perspective. Clin Oncol (R Coll Radiol) 2005 17 : 228 230
14. Klotz L. Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it? Semin Radiat Oncol 2008 18 : 2 6
15. Van der Kwast TH, Bolla M, Van Poppel H et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007 25 : 4178 4186
16. Begg CB, Riedel ER, Bach PB et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002 346 : 1138 1144
17. Wilt TJ, Shamliyan TA, Taylor BC, MacDonald R, Kane RL. Association between hospital and surgeon radical prostatectomy volume and patient outcomes: a systematic review. J Urol 2008 180 : 820 828
18. Jeldres C, Suardi N, Capitanio U et al. High surgical volume is associated with a lower rate of secondary therapy after radical prostatectomy for localized prostate cancer. BJU Int 2008 102 : 463 467 (Pubitemid 352032845)
19. Walz J, Montorsi F, Jeldres C et al. The effect of surgical volume, age and comorbidities on 30-day mortality after radical prostatectomy: a population-based analysis of 9208 consecutive cases. BJU Int 2008 101 : 826 832
20. Parkin DM. The role of cancer registries in cancer control. Int J Clin Oncol 2008 13 : 102 111
21. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry - history, content, quality and use. Dan Med Bull 1997 44 : 535 539
22. Larsen IK, Småstuen M, Johannesen TB et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009 45 : 1218 1231
23. Thompson IM. Defining high risk prostate cancer - where do we set the bar? A translational science approach to risk stratification. J Urol 2006 176 : S21 4
24. Eggener SE, Scardino PT, Carroll PR et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 2007 178 : 2260 2267